CMS proposes changes to increase Medicaid drug price transparency
![stock-doctor-prescription-bottles_900x400](/sites/default/files/styles/900x400/public/2018-04/stock-doctor-prescription-bottles_900x400.jpg?itok=P-l0VV5j)
The Centers for Medicare & Medicaid Services this week proposed changes to the Medicaid Drug Rebate Program intended to improve manufacturer data integrity and help states verify drug prices. CMS will accept comments on the proposed rule through July 25.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Aug. 15 released a state funding notice for the Cell and Gene Therapy Access Model. The CGT Access Model will…
Perspective
It’s an understatement to say everything on the national political scene is both unprecedented and unpredictable these days.To state the obvious, there will be…
Headline
The AHA July 25 urged the Centers for Medicare & Medicaid Services to maintain the uninsured rate at 8.7% under the inpatient prospective payment system…
Headline
The Department of Health and Human Services July 2 announced it will provide Medicaid and Children's Health Insurance Program coverage to incarcerated people…
Headline
The Medicaid and CHIP Payment and Access Commission (MACPAC) June 11 released its June report to Congress. The first chapter focuses on improving the…
Headline
A report released May 29 by the Government Accountability Office found a lack of state oversight on Medicaid managed care plans’ use of prior authorization for…